Seliciclib

N/A

Report date: 2026/01/06 18:01:11
NME

Base Information

Drug NameSeliciclib
Drug Alias Nameseliciclib塞利西利瑟利西利seliciclibumR-roscovitine +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 5 inhibitorsCyclin-dependent kinase 9 inhibitorsCyclin-dependent kinase 2 inhibitors +[5] 
TargetsCyclin-dependent kinase 1Cyclin-dependent kinase 5Cyclin-dependent kinase 9 +[5] 
Therapy Area/IndicationsSolid tumoursCushing SyndromeCystic Fibrosis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCentre National De La Recherche Scientifique (Cnrs)Cyclacel Pharmaceuticals IncManros Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCyclacel Pharmaceuticals IncThe University Of Texas MD Anderson Cancer CenterNational Institute Of Diabetes And Digestive And Kidney Diseases +[4] 
Active IndicationsN/A
Inactive IndicationsSolid tumoursCushing SyndromeCystic Fibrosis +[5] 

Other Information

ATC CodeN/A
Related LinksWikipedia